Shree Ganesh Remedies Ltd Q4 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Published 24 May 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹630 Cr
FY27 is expected to be a year where groundwork from FY26 translates into more visible business outcomes. FY26 was a year of consolidation, focused on groundwork rather than aggressive top-line growth.
From Shree Ganesh Remedies Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Price
₹508
Market Cap
₹630 Cr
P/E Ratio
40.8
Revenue Rank
Margin Rank
How does Shree Ganesh Remedies Ltd rank in Pharmaceuticals & Biotechnology?
Compare Shree Ganesh Remedies Ltd against every Pharmaceuticals & Biotechnology company this quarter on revenue, margins and earnings-call signals.
Shree Ganesh Remedies Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹33 Cr, net profit ₹6 Cr.
Full financials →📊 Revenue & Sales Performance
Rank 3- →FY27 is expected to be a year where groundwork from FY26 translates into more visible business outcomes.
- →Block-7 expansion to begin commercial production in Q2 FY27, supporting niche and application-led molecules including CRAMS.
- →CRAMS projects are transitioning from pilot trials to commercial trials, with momentum expected to gradually improve through FY27.
- →CRAMS business anticipated to gain traction as the year progresses.
- →No significant revenue contribution from CRAMS expected in FY26; pilot approvals ongoing, commercial scale-up anticipated in coming years.
- →Base business is stable, operating in generic markets with limited growth, expected to plateau.
- →New projects selected from customers include a mix of CRAMS, specialty chemicals, and pharma; not focused solely on CRAMS.
- →Potential revenue from new CRAMS projects exists but timing and scale depend on customer approvals and market growth.
- →Peak utilization for manufacturing operations capped at 80-85%, supporting volume growth.
- →Asset turnover ratio around 1.8 to 2x expected at peak utilization.
📈 Profitability & Margins
Rank 3- →FY26 was a year of consolidation, focused on groundwork rather than aggressive top-line growth.
- →CRAMS projects have successfully completed pilot trials in FY26; commercial trials and production expected to begin in FY27.
- →FY27 anticipated as a year where groundwork translates into visible business outcomes with growth momentum improving gradually.
- →CRAMS business expected to gain traction as the year progresses, aiding structural growth beyond the INR 120 crore range.
- →Sustainable long-term EBITDA margin guidance is 26%-28%, with initial higher margins from newly approved CRAMS products.
- →Base business is stable with limited growth, while growth will largely come from scaling mid-size CRAMS projects.
- →Asset turnover at peak utilization is approximately 1.8 to 2 times.
- →Peak manufacturing utilization of 80%-85% possible leading to better revenue from new capacity expansions (Block-7 and Block-8).
- →Management optimistic of breaking growth plateau and moving towards 15-20% growth in coming years, subject to regulatory approvals and market conditions.
🏗️ Capital Expenditure Plans
Yes- →Current focus is on expansion at the Ankleshwar plant with the recently commissioned Unit 7A, expected to commission fully in the coming year.
- →Dahej plant's common utilities construction has started and is currently under construction.
- →Future expansion plans include the Dahej plant, which will commence after full utilization of the Ankleshwar unit.
- →Timeline for Dahej plant commercialization is approximately 16 to 20 months from start, expected to start after 1 year.
- →Block-7 expansion program is on track and expected to begin commercial production in Q2 FY27, supporting niche and application-led molecules including CRAMS.
- →Pilot facility commissioned earlier this year is fully operational, accelerating new product development.
- →No specific timelines given for NSE listing; discussions are ongoing with the board.
- →Capital expenditure for Unit-7 was around INR 34 crores, with an asset turnover ratio of about 1.8 to 2 at peak utilization.
💰 Fundraising & Capital Structure
No information- →No explicit mention of any current or planned fundraising through debt or equity in the provided excerpts.
- →Discussion on capital expenditure (CAPEX) primarily focuses on Dahej and Ankleshwar plant expansions, with timelines for commissioning and commercialization mentioned.
- →Plans for NSE listing are under internal consideration but no specific timeline or active moves reported.
- →No disclosures on raising funds via equity or debt to support expansions or operations.
- →The company indicates plans for growth and capacity expansion but appears to rely on existing resources and operational cash flows.
- →If any fundraising plans arise, the management intends to discuss them with the board and announce subsequently.
📋 Order Book & Pipeline
No information- →The company has ongoing CRAMS projects with customers in Europe and Japan, with pilot trials successfully completed in Q4 FY26.
- →These projects are transitioning from pilot to commercial trials, pending customer and regulatory approvals.
- →There is no specific disclosure of orderbook size due to NDAs and competitive considerations.
- →The management refrains from giving project-specific revenue guidance but indicates a significant potential revenue contribution once approvals and commercialization progress.
- →The company expects commercial production from Block-7 expansion from Q2 FY27, supporting niche and application-led molecules including CRAMS projects.
- →Ramp-up and commercialization timelines depend on customer approvals, typically taking around 16 to 20 months for new plants like Dahej.
- →The CRAMS business is positioned for gradual growth over the next 2-3 years as projects gain traction and approvals advance.
Key Metrics
Revenue
Margin
Capex
Fundraise
Order Book
Frequently Asked Questions
What were Shree Ganesh Remedies Ltd Q4 FY26 results?
FY27 is expected to be a year where groundwork from FY26 translates into more visible business outcomes. FY26 was a year of consolidation, focused on groundwork rather than aggressive top-line growth.
What is Shree Ganesh Remedies Ltd share price analysis?
Shree Ganesh Remedies Ltd currently shows a below-average growth signal. The stock trades at a P/E of 40.8 with a market cap of ₹630 Cr. Investors should review the full earnings analysis for detailed insights.
Is Shree Ganesh Remedies Ltd planning capital expenditure?
Current focus is on expansion at the Ankleshwar plant with the recently commissioned Unit 7A, expected to commission fully in the coming year.
Keep Shree Ganesh Remedies Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.